<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430999</url>
  </required_header>
  <id_info>
    <org_study_id>PP06466</org_study_id>
    <nct_id>NCT03430999</nct_id>
  </id_info>
  <brief_title>SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PledPharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PledPharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-bline, placebo-controlled, single dose study comparing the
      pharmacokinetics (PK) and safety of PP095-01 in Japanese and non-Asian (eg, Caucasian)
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">December 18, 2017</completion_date>
  <primary_completion_date type="Actual">December 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>From signing of informed consent through the last follow up visit (up to Day 10)</time_frame>
    <description>Subject incidence of treatment-emergent adverse events (TEAEs), which may include changes in laboratory safety tests, electrocardiograms (ECG), and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose and 1 min, 15 min, 30 min, 1 hour, 4 hours, and 8 hours postdose</time_frame>
    <description>Maximum plasma concentration during a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>predose and 1 min, 15 min, 30 min, 1 hour, 4 hours, and 8 hours postdose</time_frame>
    <description>Time to reach maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-last)</measure>
    <time_frame>predose and 1 min, 15 min, 30 min, 1 hour, 4 hours, and 8 hours postdose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae</measure>
    <time_frame>4 hours post-dose and 24 hours post-dose</time_frame>
    <description>Amount of manganese and zinc excreted into urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae%</measure>
    <time_frame>4 hours and 24 hours post-dose</time_frame>
    <description>Percent of study drug manganese excreted into urine</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Chemotherapy Induced Peripheral Neuropathy (CIPN)</condition>
  <arm_group>
    <arm_group_label>Group 1 (Japanese) Calmangafodipir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 (Japanese) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Caucasian) Calmangafodipir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Caucasian) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calmangafodipir</intervention_name>
    <description>Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg</description>
    <arm_group_label>Group 1 (Japanese) Calmangafodipir</arm_group_label>
    <arm_group_label>Group 2 (Caucasian) Calmangafodipir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1 (Japanese) Placebo</arm_group_label>
    <arm_group_label>Group 2 (Caucasian) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI within 18.0 to 30.0 kg/m2 and body weight not less than 50 kg

          -  Blood pressure between 90 and 140 mmHg systolic, and no higher than 90 mmHg diastolic

          -  Non-smoker or not smoking for at least 12 months

          -  Be first generation Japanese (For Group 1 only), defined as:

               1. Born in Japan

               2. Has 2 Japanese biological parents and 4 Japanese biological grandparents

               3. Has lived outside of Japan for less than 5 years

               4. Has made no significant changes in lifestyle, including diet, since leaving Japan

        Exclusion Criteria:

          -  Clinically significant abnormal values for hematology, clinical chemistry, urinalysis,
             physical exam, vital signs, or electrocardiogram at screening

          -  Has a history of human immunodeficiency virus (HIV) antibody positive, or tests
             positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests
             positive for HBsAg or anti-HCV at Screening.

          -  Has a history of drug or alcohol abuse

          -  Has previously received calmangafodipir or mangafodipir

          -  Welders, mine workers, or other workers in occupations (current or past) where high
             manganese exposure is likely
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pyridoxal Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

